Trial site
Care Clinic Sp. Z O.O.
Katowice, 40-568, PolandEU-13 widening countryNot linked to an institution yet
- 19running trials
- 5closed trials
The trials here
What the 24 trials at this site are about, from their registry records.
- Phase
- Phase 320 trials
- Phase 23 trials
- Phase 11 trial
- Status
- Active, not recruiting13 trials
- Completed5 trials
- Recruiting5 trials
- Not yet recruiting1 trial
- Lead sponsor
- Incyte Corporation3 trials
- Novo Nordisk A/S3 trials
- Alumis Inc2 trials
- F. Hoffmann-La Roche AG2 trials
- Hoffmann-La Roche2 trials
- and 8 more
Running trials
Not yet recruiting
A Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Study of MG-K10 Humanized Monoclonal Antibody Injection in Adult and Adolescent Patients with Moderate-to-Severe Atopic Dermatitis
2025-525022-35-00· Phase 3· Hunan Mabgeek Biotech Co. Ltd.· Source
Not yet recruiting
A Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Established Atherosclerotic Cardiovascular Disease and Either Overweight or Obesity
NCT07861100· Phase 3· Novo Nordisk A/S· Source
Active, not recruiting
Study of an On-Body Injection System for Home Use of Ocrelizumab in People with Multiple Sclerosis
2025-523726-40-00· Phase 3· F. Hoffmann-La Roche AG· Source
Recruiting
A Study to Evaluate Pharmacokinetics (PK) and Safety of Subcutaneous (SC) Ublituximab Administered at Various Injection Sites and Relative Bioavailability Via Autoinjector (AI) Versus Syringe Subcutaneously in Participants With Multiple Sclerosis (MS)
NCT07503873· Phase 2· TG Therapeutics, Inc.· Source
Recruiting
A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental Vitiligo
NCT06804811· Phase 3· Incyte Corporation· Source
Active, not recruiting
Weight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide
NCT07220642· Phase 3· Novo Nordisk A/S· Source
Recruiting
Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
NCT06966401· Phase 3· Neurocrine Biosciences· Source
Active, not recruiting
A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis
NCT06934226· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib
NCT06855498· Phase 3· Incyte Corporation· Source
Recruiting
Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
NCT06786624· Phase 3· Neurocrine Biosciences· Source
Active, not recruiting
Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis
NCT06846541· Phase 3· Alumis Inc· Source
Active, not recruiting
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)
NCT06516965· Phase 3· Incyte Corporation· Source
Active, not recruiting
Evaluation of intravenous or subcutaneous administration of ublituximab in patients with autoimmune diseases
2023-509555-13-00· Phase 1· Tg Therapeutics Inc.· Source
Active, not recruiting
A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2)
NCT06220604· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
HERMES – A research study to look at how ziltivekimab works compared to placebo in people with heart failure and inflammation.
NCT05636176· Phase 3· Novo Nordisk A/S· Source
Recruiting
A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata
NCT05723198· Phase 3· Eli Lilly and Company· Source
Active, not recruiting
A Study to Learn About the Safety of Diranersen (BIIB080) Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age
NCT05399888· Phase 2· Biogen· Source
Active, not recruiting
A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis
NCT04544449· Phase 3· Hoffmann-La Roche· Source
Active, not recruiting
An Extension Study of Ublituximab in Participants With Relapsing Multiple Sclerosis
NCT04130997· Phase 3· TG Therapeutics, Inc.· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error